Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer

This article was originally published in The Tan Sheet

Executive Summary

Print ad in the June 17 New England Journal of Medicine for enteric-coated Bayer aspirin states, "Aspirin should be at the core of prevention. So why aren't more patients on aspirin?" Despite evidence that "aspirin-based therapy reduces vascular events among a broad range of at-risk patients...recent clinical studies and expanded FDA indications, millions of patients for whom aspirin may be appropriate still don't take it as part of their prevention regimen," the ad notes. "No other prevention medication is as affordable as aspirin," the ad concludes
Advertisement

Related Content

Aspirin Use In Heart Patients Increases But Still "Suboptimum" - Study
Aspirin Use In Heart Patients Increases But Still "Suboptimum" - Study
Aspirin Use In Heart Patients Increases But Still "Suboptimum" - Study

Topics

Advertisement
UsernamePublicRestriction

Register

PS089945

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel